Skip to content
Atovaquone
Malarone, Mepron (atovaquone) is a small molecule pharmaceutical. Atovaquone was first approved as Mepron on 1992-11-25. It is used to treat cerebral toxoplasmosis, malaria, and pneumocystis pneumonia in the USA. It is known to target Cytochrome b.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
respiratory tract diseasesD012140
nervous system diseasesD009422
Trade Name
FDA
EMA
Mepron (generic drugs available since 2011-01-12)
Combinations
Malarone (generic drugs available since 2011-01-12)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atovaquone
Tradename
Company
Number
Date
Products
MEPRONGSKN-020500 RX1995-02-08
1 products, RLD, RS
Show 1 discontinued
Atovaquone
+
Proguanil hydrochloride
Tradename
Company
Number
Date
Products
MALARONEGSKN-021078 RX2000-07-14
1 products, RLD, RS
MALARONE PEDIATRICGSKN-021078 RX2000-07-14
1 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
atovaquoneANDA2023-05-31
malaroneNew Drug Application2022-04-25
mepronNew Drug Application2020-10-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
cerebral toxoplasmosisEFO_0007200D016781B58.2
malariaEFO_0001068D008288B54
pneumocystis pneumoniaEFO_0007448D011020B59
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01A: Agents against amoebiasis and other protozoal diseases
— P01AX: Other agents against amoebiasis and other protozoal diseases in atc
— P01AX06: Atovaquone
— P01B: Antimalarials
— P01BB: Biguanide antimalarials
— P01BB51: Proguanil and atovaquone
HCPCS
No data
Clinical
Clinical Trials
120 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sleep initiation and maintenance disordersD007319F51.018111519655
Healthy volunteers/patients—10——2416
Sleep wake disordersD012893G471124310
SleepD012890GO_00304311—1237
DepressionD003863F33.91—13—5
Sleep apnea syndromesD012891EFO_0003877G47.3———2—2
AgingD000375GO_0007568R41.81———112
Consciousness disordersD003244———1—1
Psychomotor disordersD011596———1—1
TherapeuticsD013812———1—1
Show 9 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DementiaD003704F03——1—12
Alzheimer diseaseD000544EFO_0000249F03——1—12
Psychophysiologic disordersD011602F45.9——1——1
SchizophreniaD012559EFO_0000692F20——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Substance-related disordersD019966EFO_0003890F13—11——1
Attention deficit disorder with hyperactivityD001289EFO_0003888F90——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20—2———2
Low back painD017116HP_0003419M54.511———1
Autistic disorderD001321EFO_0003758F84.0—1———1
Autism spectrum disorderD000067877F84.0—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Dystonic disordersD020821G241————1
Marijuana abuseD002189EFO_0007191F121————1
Prostatic neoplasmsD011471C611————1
ObesityD009765EFO_0001073E66.91————1
Therapeutic equivalencyD0138101————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vascular dementiaD015140F01————11
Chronobiology disordersD021081————11
Liver cirrhosisD008103EFO_0001422K74.0————11
Endometrial neoplasmsD016889EFO_0004230————11
PainD010146EFO_0003843R52————11
Breast neoplasmsD001943EFO_0003869C50————11
Hot flashesD019584————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameATOVAQUONE
INNatovaquone
Description
Atovaquone is a naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position. It has a role as an antimalarial, an antifungal agent, an EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor, an EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor and an EC 1.10.2.2 (quinol--cytochrome-c reductase) inhibitor. It is a member of monochlorobenzenes and a hydroxy-1,4-naphthoquinone.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21
Identifiers
PDB—
CAS-ID95233-18-4
RxCUI60212
ChEMBL IDCHEMBL1450
ChEBI ID575568
PubChem CID74989
DrugBankDB01117
UNII IDY883P1Z2LT (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
MT-CYB
MT-CYB
Organism
Plasmodium falciparum
Gene name
MT-CYB
Gene synonyms
COB, CYTB, MTCYB
NCBI Gene ID
—
Protein name
Cytochrome b
Protein synonyms
Complex III subunit 3, Complex III subunit III, Cytochrome b-c1 complex subunit 3, Ubiquinol-cytochrome-c reductase complex cytochrome b subunit
Uniprot ID
Q02768
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
Atovaquone - Amneal Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,251 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
33,286 adverse events reported
View more details